Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cancer Chemotherapy Regimen for Stomach Cancer


 FAM                                                   gastric(60)
 _________________________________________________________________
  fluorouracil.... 600 mg/sqm IV days 1, 8, 28, and 35.
  adriamycin...... 30 mg/sqm IV days 1 and 28.
  mitomycin....... 10 mg/sqm IV day 1.
  FREQUENCY....... Repeat cycle every 56 days.

  reference...
    MacDonald JS.  Schein PS.  Woolley PV.  Smythe T.  Ueno W. 
    Hoth D.  Smith F.  Boiron M.  Gisselbrecht C.  Brunet R.  
    Lagarde C. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) 
    combination chemotherapy for advanced gastric cancer. Annals 
    of Internal Medicine.  93(4):533-6, 1980 Oct. 
  abstract...
    Sixty-two patients with advanced measurable gastric cancer 
    were treated with a combination chemotherapy program of 
    5-fluorouracil, doxorubicin, and mitomycin (FAM). Forty-two 
    percent of patients achieved an objective partial response. 
    The median duration of remission was 9 months and the median 
    survival for responding patients, 12.5 months. The median 
    survival for nonresponding patients was 3.5 months; all 
    patients were dead by 8 months after initiation of therapy. 
    The median survival of all 62 patients treated with FAM was 
    5.5 months. An analysis of possible prognostic variables 
    including initial performance status, resectability of the 
    primary gastric tumor, and histologic differentiation of the 
    neoplasm failed to account for differences in patient response 
    and survival. The FAM regimen was well tolerated, producing 
    only moderate bone marrow suppression. These results show that 
    patients with metastatic gastric cancer can be effectively 
    palliated with FAM chemotherapy. The efficacy of this regimen 
    should now be tested in patients with less advanced stages of 
    this disease. 
 

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.